Last reviewed · How we verify
JNJ-64457107
At a glance
| Generic name | JNJ-64457107 |
|---|---|
| Also known as | ADC1013 |
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers (PHASE2, PHASE3)
- Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients (PHASE1, PHASE2)
- A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JNJ-64457107 CI brief — competitive landscape report
- JNJ-64457107 updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI